Sagittarius Life Science Corp (TPEX:3205)
Taiwan · Delayed Price · Currency is TWD 46.80
0.00 (0.00%)
Sep 8, 2026, 1:30 PM CST
Sagittarius Life Science Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 467.69 | 346.08 | 467.75 | 440.46 | 529.07 | 587.61 | |
Revenue Growth | 4.86% | -26.01% | 6.20% | -16.75% | -9.96% | 5.27% |
Cost of Revenue | 425.56 | 288.37 | 386.64 | 368.98 | 446.5 | 487.07 |
Gross Profit | 42.12 | 57.71 | 81.11 | 71.48 | 82.56 | 100.54 |
Selling, General & Admin | 59.71 | 94.72 | 124.78 | 114.02 | 142.1 | 158.98 |
Research & Development | 15.18 | 21.5 | 17.89 | 21.83 | 22.69 | 31.58 |
Operating Expenses | 74.89 | 116.22 | 142.67 | 135.85 | 164.79 | 190.55 |
Operating Income | -32.77 | -58.51 | -61.56 | -64.38 | -82.23 | -90.01 |
Interest Expense | -0.26 | -0.07 | -0.21 | -0.08 | -0.23 | -0.39 |
Interest & Investment Income | 13.03 | 9.77 | 4.93 | 4.59 | 1.48 | 1.26 |
Earnings From Equity Investments | - | - | - | - | -2.98 | - |
Currency Exchange Gain (Loss) | 0.19 | 0.05 | 1.49 | -0.11 | 2.86 | -1.22 |
Other Non Operating Income (Expenses) | 2.13 | -0.52 | 2.69 | 3.24 | 3.38 | 2.92 |
EBT Excluding Unusual Items | -17.67 | -49.28 | -52.66 | -56.75 | -77.72 | -87.45 |
Gain (Loss) on Sale of Investments | -1.34 | -0.47 | - | - | - | - |
Gain (Loss) on Sale of Assets | 1.12 | -0.13 | 2.98 | -0.08 | 0.01 | -0.01 |
Asset Writedown | 0.15 | - | - | - | - | - |
Other Unusual Items | - | - | - | - | 1.21 | - |
Pretax Income | -17.75 | -49.88 | -49.68 | -56.82 | -76.5 | -87.46 |
Income Tax Expense | - | - | - | - | -0.01 | - |
Earnings From Continuing Operations | -17.75 | -49.88 | -49.68 | -56.82 | -76.49 | -87.46 |
Minority Interest in Earnings | 1.28 | 0.31 | 1.15 | 1.79 | 2.29 | 1.04 |
Net Income | -16.47 | -49.56 | -48.53 | -55.04 | -74.2 | -86.42 |
Net Income to Common | -16.47 | -49.56 | -48.53 | -55.04 | -74.2 | -86.42 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 68 | 54 | 33 | 33 | 33 | 33 |
Shares Outstanding (Diluted) | 68 | 54 | 33 | 33 | 33 | 33 |
Shares Change | 85.65% | 65.82% | - | - | - | -0.22% |
EPS (Basic) | -0.24 | -0.92 | -1.49 | -1.69 | -2.28 | -2.66 |
EPS (Diluted) | -0.24 | -0.92 | -1.49 | -1.69 | -2.28 | -2.66 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -261.16 | -36.45 | -47.77 | -71.38 | -53.98 | -37.4 |
Free Cash Flow Per Share | -3.86 | -0.68 | -1.47 | -2.19 | -1.66 | -1.15 |
Gross Margin | 9.01% | 16.68% | 17.34% | 16.23% | 15.60% | 17.11% |
Operating Margin | -7.01% | -16.91% | -13.16% | -14.62% | -15.54% | -15.32% |
Profit Margin | -3.52% | -14.32% | -10.38% | -12.50% | -14.03% | -14.71% |
Free Cash Flow Margin | -55.84% | -10.53% | -10.21% | -16.21% | -10.20% | -6.37% |
EBITDA | -30.45 | -53.17 | -53.89 | -57.68 | -74.85 | -81.43 |
EBITDA Margin | -6.51% | -15.36% | -11.52% | -13.10% | -14.15% | -13.86% |
D&A For EBITDA | 2.31 | 5.34 | 7.67 | 6.7 | 7.38 | 8.59 |
EBIT | -32.77 | -58.51 | -61.56 | -64.38 | -82.23 | -90.01 |
EBIT Margin | -7.01% | -16.91% | -13.16% | -14.62% | -15.54% | -15.32% |